Here are five things to know:
1. The study will enroll 450 patients at 15 clinical sites throughout the U.S.
2. BioBurst Fluid, a cellular allograft found in umbilical cord blood, will be used in the study. The fluid has exhibited promising results in spinal fusion procedures.
3. Currently valued at $1.6 billion, the global spine biologics market is expected to reach $2.2 billion by 2022 and represents a significant opportunity for innovative biologic products.
4. Patients with poor health or low healing recovery would benefit most from successful studies investigating cellular content’s impact on spinal fusion.
5. Burst Biologics CEO Chris Jones said, “An open registry allows us to evaluate success rates in complex cases that would otherwise be excluded from studies… We want to demonstrate to spine surgeons and third-party payers that BioBurst Fluid can be successful in their more challenging patients.”
More articles on devices:
Integra expands Cadence Total Ankle System — 5 notes
Implanet reports 18% jump in 2016 revenue: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
